2-[(9S)-7,10-bis(carboxymethyl)-9-[[4-(ethanethioylamino)phenyl]methyl]-1-oxa-4,7,10-triazacyclododec-4-yl]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(9S)-7,10-bis(carboxymethyl)-9-[[4-(ethanethioylamino)phenyl]methyl]-1-oxa-4,7,10-triazacyclododec-4-yl]acetic acid
• 化学式: C₂₃H₃₄N₄O₇S
• 分子量: 510.6
• InChiKey: VOTQCLCMZXJWAF-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.3
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  175
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• Chelated PSMA Inhibitors
  申请人：Berkman Clifford

  公开号：US20140241985A1

  公开（公告）日：2014-08-28

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文提供了化合物，其用于：(1)检测和/或鉴定呈现PSMA的细胞的诊断方法；(2)包含本发明化合物和药学可接受稀释剂的组合物；以及(3)成像前列腺癌细胞的方法。
• Albumin-binding PSMA inhibitors
  申请人：Cancer Targeted Technology LLC

  公开号：US11147889B2

  公开（公告）日：2021-10-19

  Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).

  本文提供了式 (I) 化合物或其药学上可接受的盐，其中 L1 和 L2 各自独立地为共价键或二价连接基团，R 为可检测标签或治疗药物，B 为白蛋白结合分子。还提供了包括式（I）化合物和药学上可接受的载体的组合物，以及使用式（I）化合物对前列腺癌细胞成像的方法。
• Chelated PSMA inhibitors
  申请人：Cancer Targeted Technology LLC

  公开号：US11225496B2

  公开（公告）日：2022-01-18

  Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells.

  本文提供了式（I）化合物或其药学上可接受的盐。还提供了包括式（I）化合物和药学上可接受的载体的组合物，以及前列腺癌细胞成像的方法。
• Albumin-Binding PSMA Inhibitors
  申请人：Cancer Targeted Technology LLC

  公开号：US20200061218A1

  公开（公告）日：2020-02-27

  Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L 1 and L 2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).
• BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF
  申请人：BicycleRD Limited

  公开号：US20210079045A1

  公开（公告）日：2021-03-18

  The present invention provides compounds, compositions thereof, and methods of using the same.